$2.01
5.79% yesterday
Nasdaq, Nov 25, 09:49 pm CET
ISIN
US95075A1079
Symbol
HOWL
Sector
Industry

Werewolf Therapeutics Inc Stock price

$2.00
-1.00 33.33% 1M
-2.88 59.02% 6M
-1.86 48.19% YTD
-0.52 20.63% 1Y
-12.96 86.63% 3Y
-14.10 87.58% 5Y
-14.10 87.58% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.10 5.26%
ISIN
US95075A1079
Symbol
HOWL
Sector
Industry

Key metrics

Market capitalization $89.13m
Enterprise Value $3.08m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.91
P/S ratio (TTM) P/S ratio 26.29
P/B ratio (TTM) P/B ratio 0.98
Revenue growth (TTM) Revenue growth -86.84%
Revenue (TTM) Revenue $3.39m
EBIT (operating result TTM) EBIT $-66.21m
Free Cash Flow (TTM) Free Cash Flow $-46.85m
Cash position $122.83m
EPS (TTM) EPS $-1.50
P/E forward negative
P/S forward 47.35
EV/Sales forward 1.64
Short interest 4.80%
Show more

Is Werewolf Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Werewolf Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Werewolf Therapeutics Inc forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Werewolf Therapeutics Inc forecast:

Buy
100%

Financial data from Werewolf Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
3.39 3.39
87% 87%
100%
- Direct Costs 1.83 1.83
28% 28%
54%
1.55 1.55
93% 93%
46%
- Selling and Administrative Expenses 16 16
16% 16%
459%
- Research and Development Expense 50 50
5% 5%
1,486%
-64 -64
69% 69%
-1,899%
- Depreciation and Amortization 1.83 1.83
28% 28%
54%
EBIT (Operating Income) EBIT -66 -66
63% 63%
-1,953%
Net Profit -62 -62
67% 67%
-1,832%

In millions USD.

Don't miss a Thing! We will send you all news about Werewolf Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Werewolf Therapeutics Inc Stock News

Neutral
GlobeNewsWire
6 days ago
WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., Pr...
Neutral
GlobeNewsWire
19 days ago
- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals -
Neutral
GlobeNewsWire
about 2 months ago
WATERTOWN, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that two posters will be presented at the upcoming Society for Immunot...
More Werewolf Therapeutics Inc News

Company Profile

Werewolf Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Cambridge, MA.

Head office United States
CEO Dan Hicklin
Employees 47
Founded 2017
Website www.werewolftx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today